Physician profile
Chris Schabinger
NPI 1558850883
$6,900.83
in general payments reported to CMS, 2019-2025
32 companies · $3,138 in 2025
The $3,138 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $605 · 2023: $1,021 · 2024: $2,020 · 2025: $3,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,560 · Travel and Lodging: $619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,560.08 |
| Travel and Lodging | $618.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,017.88 | 2025 | Symplicity G3 |
| Novartis Pharmaceuticals Corporation | $994.51 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $865.18 | 2022-2025 | Lifevest |
| Amgen INC. | $774.25 | 2022-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $758.70 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $488.20 | 2022-2025 | |
| Heartflow, INC. | $351.43 | 2024-2025 | |
| Edwards Lifesciences Corporation | $176.61 | 2022-2025 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $172.20 | 2023-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $140.69 | 2024 | Watchman Access System |
| Philips North America LLC | $133.64 | 2024-2025 | (Ck4) Mcot, (Ck7) Extended Holter, Extended Holter |
| Novo Nordisk INC | $118.87 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $106.14 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.55 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $70.76 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $62.50 | 2024-2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $56.13 | 2025 | Amvuttra |
| Kestra Medical Technology Services, INC. | $53.96 | 2023-2024 | Assure Wcd |
| Inspire Medical Systems, INC. | $52.07 | 2024 | Inspire |
| Actelion Pharmaceuticals US, INC. | $46.68 | 2022 | |
| Janssen Pharmaceuticals, INC | $46.32 | 2022-2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $44.25 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $43.25 | 2023 | Arcalyst |
| Itamar Medical INC | $33.95 | 2025 | Watchpatone |
| Esperion Therapeutics, INC. | $33.71 | 2025 | Nexletol |
| Daiichi Sankyo INC. | $31.66 | 2023-2024 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $27.28 | 2022-2024 | Farxiga |
| Abbott Laboratories | $21.04 | 2022 | |
| Ossur Americas, INC. | $20.60 | 2025 | |
| Tactile Systems Technology INC | $19.40 | 2025 | Flexitouch Plus, Nimbl |
| Lexicon Pharmaceuticals, INC. | $16.74 | 2024 | |
| Bridgebio Pharma, INC. | $16.68 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Schabinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.